IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease

Atherosclerosis. 2015 Aug;241(2):498-501. doi: 10.1016/j.atherosclerosis.2015.06.008. Epub 2015 Jun 10.

Authors

Alberico L Catapano¹, Brian A Ference²

Affiliations

¹ Department of Pharmacological and Biomolecular Sciences University of Milan and IRCCS Multimedica, Via Balzaretti 9, 20133 Milano, Italy. Electronic address: alberico.catapano@unimi.it.
² Division of Cardiovascular Medicine Wayne State University School of Medicine UHC, 2E2 Detroit, MI 48202, USA.

PMID: 26091974
DOI: 10.1016/j.atherosclerosis.2015.06.008

No abstract available

MeSH terms

Cardiovascular Diseases / blood*
Cardiovascular Diseases / etiology
Cardiovascular Diseases / genetics*
Cholesterol, LDL / blood*
Drug Approval
Ezetimibe / administration & dosage
Genetic Predisposition to Disease
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
Membrane Proteins / genetics
Membrane Transport Proteins
Mendelian Randomization Analysis
Randomized Controlled Trials as Topic
Research Design

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Membrane Proteins
Membrane Transport Proteins
NPC1L1 protein, human
Ezetimibe